Skip to main content
Oxford Biomedica PLC logo

Oxford Biomedica PLC — Investor Relations & Filings

Ticker · OXB ISIN · GB00BDFBVT43 LEI · 213800S1GVQNXQ15K851 IL Manufacturing
Filings indexed 877 across all filing types
Latest filing 2026-05-11 AGM Information
Country GB United Kingdom
Listing IL OXB

About Oxford Biomedica PLC

https://www.oxb.com/

Oxford Biomedica (OXB) is a global contract development and manufacturing organization (CDMO) specializing in cell and gene therapy. A pioneer in the field, the company has extensive experience in viral vectors, the enabling technology for many advanced therapies. OXB provides end-to-end services to pharmaceutical and biotechnology partners, supporting programs from preclinical development through to commercial launch. Its core expertise includes the development and GMP manufacturing of various vector types, including lentivirus, adeno-associated virus (AAV), and adenovirus. The company offers proprietary technologies like its LentiVector™ platform, the first commercially approved lentiviral system, and its inAAVate™ platform for AAV, in addition to tech-transfer capabilities.

Recent filings

Filing Released Lang Actions
Print of AGM Resolutions
AGM Information Classification · 93% confidence The document is the formal record of resolutions passed at the Annual General Meeting of Oxford Biomedica plc on 7 May 2026, detailing ordinary and special resolutions adopted by shareholders (adoption of reports, reappointments, share authorities, etc.). It is part of the AGM materials rather than an earnings release, financial report, or notice of voting results with tallies. It fits the AGM Information category.
2026-05-11 English
AGM Minutes
Regulatory Filings
2026-05-07 English
Result of AGM
AGM Information
2026-05-07 English
Total Voting Rights
Declaration of Voting Results & Voting Rights Announcements
2026-05-01 English
Admission to Trading
Regulatory Filings
2026-04-30 English
Admission to Trading Application
Share Issue/Capital Change Classification · 85% confidence The document is an RNS announcement titled “Admission to Trading Application,” describing the allotment and admission to trading of new ordinary shares under employee share schemes (LTIP, SAYE, ESOS). It is not a report publication or regulatory filing fallback, but a notification of a share issue and capital change. Therefore it falls under Share Issue/Capital Change (SHA).
2026-04-27 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.